Why is Mankind Pharma falling/rising?

As of 19-Aug, Mankind Pharma Ltd's stock price is currently at Rs 2,491.45, reflecting an increase of Rs 16.45, or 0.66%. The stock has shown a positive performance today, outperforming its sector by 0.79% and has been gaining for the last two days with a total return of 0.91% during this period. Despite a recent decline of 6.09% over the past month, the stock has performed well over the past week, gaining 2.42%. The company's strong fundamentals are supported by high management efficiency, evidenced by a return on equity (ROE) of 17.21%, and a low debt to EBITDA ratio of 0.69, indicating a solid ability to service debt. Additionally, the company has demonstrated healthy long-term growth with net sales increasing at an annual rate of 18.86% and operating profit at 17.94%. High institutional holdings at 24.58% suggest that knowledgeable investors are confident in the company's fundamentals.
In the broader market context, Mankind Pharma's short-term return of 2.42% over the past week outperformed the Sensex, which increased by 1.76% during the same period. However, the stock's year-to-date performance shows a decline of 13.40%, contrasting with the Sensex's gain of 4.49%. This divergence indicates that while the stock may be experiencing a short-term recovery, it has struggled significantly in the longer term compared to the broader market. The recent drop in investor participation, with delivery volume falling by 4.94% against the five-day average, may also be a concern, suggesting that while the stock is gaining, there may be underlying issues affecting investor confidence.